New prospects for the development of a vaccine against human immunodeficiency virus type 1. An overview

Comptes Rendus de l'Academie des Sciences - Serie III

Volumn 322, Issue 11, 1999, Pages 959-966

  Girard, Marc ^a,b   Habel, André ^a   Chanel, Chantal ^a  

^a INSTITUT PASTEUR   (France)

^b BIOMÉRIEUX   (France)

Author keywords

AIDS; DNA vaccines lentiviruses; Poxvirus vectors; SIV

Indexed keywords

AIDAVAX; CHEMOKINE; CYTOKINE; DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DELETION MUTANT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; KILLER CELL; META ANALYSIS; MUCOSAL IMMUNITY; NONHUMAN;

ALPHAVIRUS; ANIMALIA; ANKARA; EQUIDAE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; PAN (APE); POXVIRIDAE; SEMLIKI FOREST VIRUS; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS; VACCINIA; VACCINIA VIRUS; VENEZUELAN EQUINE ENCEPHALITIS VIRUS;

EID: 0033230320     PISSN: 07644469     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0764-4469(00)87193-0     Document Type: Conference Paper

References (69)

1. Ferrari G., Humphrey W., McElrath M.J., Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers, Proc. Natl. Acad. Sci. USA 94 (1997) 1396-1401.
2. Cao H., Kanke P., Sankali J.L., Cytotoxic T lymphocyte crossreactivity among different human immunodeficiency virus type 1 classes: Implication for vaccine development, J. Virol. 71 (1997) 8615-8623.
3. Weber J.H., Fenyö E.M., Beddows S., Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype, J. Virol. 70 (1996) 7827-7832.
4. Moore J.P., Cao Y., Len J., Inter- and intraclade neutralization of human immunodeficiency virus type 1: Genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes, J. Virol. 70 (1996) 427-444.
5. Kostrikis L.G., Cao Y., Ngai H., Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: Lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement, J. Virol. 70 (1996) 445-458.
6. Nyambi P.N., Nkengasong J., Levi P., Multivariate analysis of human immunodeficiency virus type 1 neutralization data, J. Virol. 70 (1996) 6235-6243.
7. Beddows S., Lousirirotchanakul S., Cheingsong-Popov R., Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: Role of V3 specific antibodies, J. Gen. Virol. 70 (1998) 7782.
8. Spenlehauser C., Sagarosti S., Fleury H.J., Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell line-adapted strains of human immunodeficiency virus type 1, J. Virol. 72 (1998) 9855-9864.
9. VanCott T.C., Polonis V.R., Loomis L.D., Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1, AIDS Res. Hum. Retroviruses 11 (1995) 1379-1391.
10. + lymphocytes, Science 283 (1999) 857-860.
11. Johnson R.P., Macaque models for AIDS vaccine development, Curr. Opin. Immunol. 8 (1996) 554-560.
12. Reimann K.A., Li J.T., Vezzey R., A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys, J. Virol. 70 (1996) 6922-6928.
13. Daniel M.D., Kirchhoff F., Czajak S.C., Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene, Science 2158 (1992) 1938-1941.
14. Almond N., Kent K., Cranage M., Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells, Lancet 345 (1995) 1342-1344.
15. Heeney J.L., Primate models for AIDS vaccine development, AIDS 10 S 1938 (suppl. A). 115S-122
16. Shibata R., Sleman C., Czajak S.C., Live attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus, J. Virol. 71 (1997) 8141-8148.
17. Baba T.W., Liska V., Khimani A.H., Live attenuated multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques, Nat. Med. 5 (1995) 194-203.
18. Johnson R.P., Glickman R.L., Yang J.Q., Induction of vigorous cytotoxic T lymphocyte responses by live attenuated simian immunodeficiency virus, J. Virol. 71 (1997) 7711-7718.
19. + T lymphocytes from macaques immunized with live attenuated SIV, J. Virol. 72 (1998) 6315-6324.
20. + T cells, Science 270 (1995) 1811-1815.
21. + lymphocytes can control HIV infection in vitro by suppressing virus replication, Science 234 (1986) 1563.
22. Lehner T., Wang Y., Tao L., CD8-suppressor factor and beta-chemokine function in a complementary mechanism to cognate immunity, Immunol. Lett. 66 (1999) 171-176.
23. + nef-specific cytotoxic T cells in vaccinated macaques, Nat. Med. 1 (1995) 1167-1173.
24. Benson J., CHougnet C, Robert-Guroff M., Recombinant vaccine induced protection against the highly pathogenic simian immunodeficiency virus SIVmac251: Dependence on route of challenge exposure, J. Viral. 72 (1998) 4170-4182.
25. Fowke K.R., Ngelherte N.J., Kimani J., Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya, Lancet 348 (1996) 1347-1351.
26. Rowlands-Jones S.L., Dong T., Fowke K.R., Cytotoxic T-cell response to multiple conserved HIV epitopes in HIV-1 resistant prostitutes in Nairobi, J. Clin. Invest. 102 (1998) 1758-1765.
27. Rowlands-Jones S., Sutton J., Ariyoshi K., HIV-specific cytotoxic T-cells in HIV-1 exposed but uninfected Gambian women, Nat. Med. 1 (1996) 59-64.
28. Haynes B.F., Pantaleo G., Fauci A.S., Toward an understanding of the correlates of protective immunity to HIV infection, Science 271 (1996) 324-328.
29. Girard M., Meignier B., Barré-Sinoussi F., Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1, J. Virol. 69 (1996) 6239-6248.
30. Berman M.W., Murphy K.K., Wrin T., Protection of MNgp120 immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1, J. Infect. Dis. 193 (1996) 52-59.
31. Excler J.L., Plotkin S.A., The prime boost concept applied to HIV preventive vaccines, AIDS 11 (suppl. A) (1997) S127-S137.
32. Pialoux G., Excler J.L., Rivière Y., A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN), AIDS Res. Hum. Retroviruses 11 (1995) 373-381.
33. Fleury B., Janvier G., Pialoux G., Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type, (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp160 of HIV-1 and boosted with a recombinant gp160, J. Infect. Dis. 174 (1996) 734-738.
34. Plotkin S.A., Cadoz M., Meignier B., The safety and use of canarypox vectored vaccines, Dev. Biol. Stand. 84 (1995) 165-170.
35. Mayr A., Hochstein-Mintzel V., Stickl H., Abstammung, eidgenschaften und verwendung des attenuirten vaccinia. -Stammes MVA, Infektion 3 (1975) 6-14.
36. Moss B., Carroll M.W., Wyatt L.S., Host-range restricted, non-replicating vaccinia virus vectors as vaccine candidates, Adv. Exp. Med. Biol. 397 (1996) 7-13.
37. Paoletti E., Taylor J., Meignier B., Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC, Dev. Biol Stand. 84 (1995) 159-163.
38. Davis N.L., Brown K.W., Johnston R.E., A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge, J. Virol. 70 (1996) 3781-3787.
39. Frolov I., Hoffman T.A., Pragai B.M., Alphavirus-based expression vectors: Strategies and applications, Proc. Natl. Acad. Sci. USA 93 (1996) 11371-11377.
40. Tubukelas I., Berglund P., Fluton M., Liljeström P., Alpha virus expression vectors and their use as recombinant vaccines - A minireview, Gene 190 (1997) 191-195.
41. Smerdou C., Liljeström P., Two-helper RNA system for production of recombinant Semliki Forest virus particles, J. Virol. 73 (1999) 1092-1098.
42. Francis D.P., Gregory T., McElrath M.J., Advancing AIDSVAX to phase 3. Safety, immunogenicity and plans for phase 3,AIDS Res. Hum. Retroviruses 14 (suppl. A) (1998) S325-S331.
43. Egan M.A., Pavlat W.A., Tartaglia J., Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responders in seronegative adults by a non replicating, host-range-restricted canary-pox vector (ALVAC) carrying the HIV-1 MN env gene, J. Infect. Dis. 171 (1995) 1623-1627.
44. Hirsch V., Fuerst T.R., Sutter G., Patterns of viral replication correlate with outcome in SIV-infected macaques: Effects of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara, J. Virol. 70 (1996) 3741-3752.
45. Seth A., Ourmanov I., Kuroda M.J., Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag-pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility class I/peptide tetramer, Proc. Natl. Acad. Sci. USA 95 (1999) 10112-10116.
46. Hanke T., Neumann V.C., Blanchard T.J. et al., Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime, Vaccine 17 (1999) 589-596.
47. Kent S.J., Zhao A., Best S.J., Enhanced T-cell immunogenicity and protective efficacy of a HIV-1 vaccine regimen consisting of consecutive priming with DNA and boosting with rFPV, J. Virol. 72 (1998) 10180-10188.
48. Robinson H.L., Montefiori D.C., Johnson R.P., Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and rFPV booster immunizations, Nat. Med. 5 (1999) 526-534.
49. Kim J.J., Ayyaroo V., Bagarazzi M.L., In vivo engineering of a cellular immune response by co-administration of IL-12 expression vector with a DNA immunogen, J. Immunol. 158 (1997) 816-826.
50. Kim J.J., Trivedi N.N., Nottingham L.K., Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens, Eur. J. Immunol. 28 (1998) 1089-1103.
51. Leong K.H., Ramsay A.J., Boyle D.B., Ramshaw I.A., Selective induction of immune responses by cytokines co-expressed in rFPV, J. Virol. 68 (1994) 8125-8130.
52. Boyer J.D., Ugen K.E., Wang, Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination, Nat. Med. 3 (1997) 526-532.
53. Letvin N.L., Montefiori D.C., Yasutomi Y., Potent, protective anti-HIV immune responses generated by model HIV envelope DNA plus protein vaccination, Proc. Natl. Acad. Sci. USA 94 (1997) 9378-9383.
54. Atkins G.J., Shehan B.J., Liljeström P., Manipulation of the Semliki Forest virus genome and its potential for vaccine construction, Mol. Biotechnol. 5 (1996) 33-38.
55. Van DePerre P., Simon A., Hitimana D.G., Infective and anti-infective properties of breast milk from HIV-1 infected women, Lancet 341 (1993) 914-918.
56. Kuroda M.J., Schmitz J.E., Charini W.A., Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys, J. Immunol. 162 (1999) 5127-5133.
57. Lehner T., Wang Y., Cranage M., Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques, Nat. Med. 2 (1996) 767-775.
58. Cullen B.R., The HIV-1 tat protein; An RNA sequence-specific processing factor, Cell 63 (1990) 655-657.
59. Cullen B.R., Mechanism of action of regulatory proteins encoded by complex retroviruses, Microb. Rev. 56 (1992) 375-394.
60. Milim M.N., Hauber J., Fenrick R., Cullen B.R., Immunodeficiency virus rev transactivator modulates the expression of the viral regulatory genes, Nature 335 (1988) 181-183.
61. Truant R., Cullen B.R., The arginine rich domains present in human immunodeficiency virus type 1 tat and rev function as direct import in beta-dependent nuclear localization signals, Mol. Cell Biol. 19 (1999) 1210-1217.
62. VanBaalen C.A., Pontesilli O., Huisman R.C., HIV-1 rev and tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS, J. Gen. Virol. 8 (1997) 1913-1918.
63. Zagury J.F., Still A., Blattner W., Antibodies to the HIV-1 tat protein correlated with nonprogression to AIDS: A rationale for the use of the tat toxoid as an HIV-1 vaccine, J. Hum. Virol. 1 (1998) 282-292.
64. Goldstein G., HIV-1 tat protein as a potential AIDS vaccine, Nat. Med. 1 (1996) 960-964.
65. Cafaro A., Caputo A., Fracasso C., Control of SHIV 89. 6 p-infection of cynomolgus monkeys by HIV-1 tat protein vaccine, Nat. Med. 6 (1999) 643-650.
66. Gallo R.C., Tat as one key to HIV-induced immunopathogenesis and tat toxoid as an important component of a vaccine, Proc. Natl. Acad. Sci. USA 96 (1999) 8324-8326.
67. Hone D.M., Wu S., Powell R.J., Optimization of live oral Salmonella-HIV-1 vaccine vectors for the induction of HIV-specific mucosal and systemic immune responses, J. Biotech. 44 (1996) 203-207.
68. Kuroda M.J., Schmitz J.E., Charini W.A., Comparative analysis of cytotoxic T lymphocytes in lymph nodes and peripheral blood of simian immunodeficiency virus-infected rhesus monkeys, J. Virol. 73 (1999) 1573-1579.
69. LaCasse R.A., Follis K.E., Trajey M., Fusion-competent vaccines: Broad neutralization of primary isolates of HIV, Science 283 (1999) 357-362.